DNAJC12

Across TCGA pan-cancer cohorts, DNAJC12 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DNAJC12 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAJC12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DNAJC12 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where DNAJC12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.934	0.238	.017	15	view →
LSCC	DFS	Median	II,III,IV	0.658	0.885	.017	13	view →
LUAD	DFS	Median	III,IV	0.409	0.922	.024	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DNAJC12–PDAC (DFS)

Open the PDAC breakdown →